All Title Author
Keywords Abstract

-  2018 


DOI: 10.16781/j.0258-879x.2018.05.0465

Keywords: 急性髓系白血病 精准治疗 微小残留病 异基因造血干细胞移植
acute myeloid leukemia precision treatment minimal residual disease allogeneic stem cell transplantation

Full-Text   Cite this paper   Add to My Lib


Acute leukemia is a malignant tumor with the highest morbidity and mortality in patients younger than 35 years old. Three-year overall survival of middle-risk patients receiving conventional chemotherapy is only 30%-50%, although the stratified chemotherapy based on cell and molecular genetics has improved the overall survival in recent years. To further optimize the treatment, we used flow cytometry in combination with fluorescent in situ hybridization to detect the competing of leukemia stem cells with hemopoietic stem cell, which could diagnose the relapse of patients 2-3 months ahead of time, thus allowing early intervention and improving the survival rate. In allogeneic hematopoietic stem cell transplantation, we have designed a novel conditioning regimen, which balanced the graft-versus-host disease and graft-versus-leukemia effect and reduced transplant-related mortality. This is a new focus on acute leukemia treatment and a further extension of precision therapy in leukemia


comments powered by Disqus